Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.51
-0.41 (-5.92%)
May 18, 2026, 4:00 PM EDT - Market closed
Solid Biosciences Employees
Solid Biosciences had 121 employees as of December 31, 2025. The number of employees increased by 21 or 21.00% compared to the previous year.
Employees
121
Change (1Y)
21
Growth (1Y)
21.00%
Revenue / Employee
n/a
Profits / Employee
-$1,584,959
Market Cap
640.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | 21 | 21.00% |
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsSLDB News
- 5 days ago - Solid Biosciences price target lowered to $16 from $17 at Wedbush - TheFly
- 5 days ago - Solid Biosciences price target raised to $18 from $17 at Piper Sandler - TheFly
- 6 days ago - Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 days ago - Solid Biosciences Quarterly report: Q1 2026 - Filings
- 6 days ago - Solid Biosciences Earnings release: Q1 2026 - Filings
- 11 days ago - Solid Biosciences doses part participant in IMPACT DUCHENNE study - TheFly
- 11 days ago - Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy - GlobeNewsWire
- 17 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire